TIPS for CEO's
Patent Expiry Status of select drugs
| No. |
Molecule |
Patent Holder | Global Sales (U.S. $) |
Patent Expiry |
| 7 |
Omeprazole |
Astra |
3675 million |
2001 |
| 8 |
Fluexitine |
Eli Lilly |
2356 million |
2001 |
| 9 |
Amlodipine |
Pfizer |
1795 million |
2001 |
| 10 |
Lovastatin |
Merck |
1255 million |
2001 |
| 11 |
Amoxicillin |
SKB |
1354 million |
2002 |
| 12 |
Ciprofloxacin |
Bayer |
1290 million
| 2003 |
| 13 |
Loratadine |
Schering Plough
| 1069 million |
2004 |
| 14 |
Simvastatin
| Merck |
2800 million |
2005 |
| 15 |
Sertraline |
Pfizer |
1337 million |
2005 |
| 16 |
Clarithromycin |
Abbott |
1150 million |
2005 |
| 17 |
Paroxetine |
SKB |
1101 million |
2005 |
| 18 |
Pravastat |
BMS |
1075 million |
2005 |
| 19 |
Cyclosporine |
Novartis |
1300 million |
2011 |
| 20 |
Erythropoetin |
Amgen |
1150 million |
2013 |
back to top
Pharma M&A list here